Tumor infiltration of >50 CD8 T lymphocytes/mm2 improved patient survival significantly (HR 0.643, CI 0.421–0.983, p = 0.042) while a higher UICC stage (Stage I-III vs. Stage IV) was associated with worse survival (HR 2.962, CI 1.785–4.915, p < 0.001). Here, CD8A is linked to neoplasm.